NCT01706120进行中（未招募）4 期
A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS
National Cancer Institute, Naples47 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
- 试验地点
- 47
- 主要终点
- expression of soluble and tissutal biomarkers
研究概览
简要总结
The addition of bevacizumab to first-line chemotherapy has been shown to improve progression free survival for patients with ovarian cancer. The purpose of this study is to explore the potential role of clinical and biologic factors in identifying those patients who benefit most from this combined therapy in terms of progression free and overall survival.
详细描述
MITO-16 - MANGO-OV2 is a single-arm, open-label, non-comparative, multicenter, phase IV study. Patients will receive a combination of bevacizumab, paclitaxel and carboplatin as first line treatment (in-label dose and scheduling). This is an exploratory study attempting to identify potential prognostic clinical factors(such as hypertension) and prognostic biologic factors. Overall, 2 types of biomarkers are considered. Dynamic biomarkers are those expressing the changing nature of the disease in relation to the treatment or simply the tumour progression, these are typically not inherited. Genetic biomarkers are typically inherited and are expression of some characteristics potentially able to interfere with the treatment effect (i.e. Pharmacogenomics).
The safety of this regimen in routine clinical practice will also be described.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients ≥18 years of age.
- •Patients with histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma, including mixed Mullerian Tumours Or Recurrent early stage epithelial ovarian or fallopian tube carcinoma treated with surgery alone.
- •FIGO stage IIIB & C or IV
- •ECOG Performance Status of 0-
- •Life expectancy of at least 12 weeks.
- •Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.
- •Availability of tumour samples for molecular analyses
排除标准
- •Cancer related
- •Ovarian tumours with low malignant potential (i.e. borderline tumours)
- •Previous systemic anti-cancer therapy for advanced ovarian cancer.
- •History or evidence of brain metastases or spinal cord compression.
- •History or evidence of synchronous primary endometrial carcinoma, unless all of the following criteria related to the endometrial carcinoma are met:
- •stage ≤Ia
- •no more than superficial myometrial invasion
- •no lymphovascular invasion
- •not poorly differentiated (grade 3 or papillary serous or clear cell carcinoma).
- •Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
- •Other-treatment related
- •Any prior radiotherapy to the pelvis or abdomen.
- •Surgery (including open biopsy) within 4 weeks prior to the first bevacizumab dose or planned (In this case the patient can be enrolled but the administration of bevacizumab should be omitted at first cycle).
- •Current or recent (within 10 days prior to the first study drug dose) use of full-dose oral or parenteral anticoagulant or thrombolytic agent for therapeutic purposes (except for central venous access patency, in which case international normalized ratio [INR] must be maintained below 1.5). Post operative prophylaxis with low molecular weight heparin sc is allowed.
- •Current or recent (within 30 days of first study dosing) treatment with another investigational drug.
- •Laboratory related
- •Inadequate bone marrow function: ANC: <1.5 x 109/l, or platelet count <100 x 109/l or Haemoglobin <9 g/dl. Patients may be transfused to maintain haemoglobin values ≥9 g/dl.
- •Inadequate coagulation parameters:
- •activated partial thromboplastin time (APTT) >1.5 xULN or
- •INR >1.5
- •Inadequate liver function, defined as:
- •serum (total) bilirubin >1.5 x the upper limit of normal (ULN) for the institution
- •AST/SGOT or ALT/SGPT >2.5 x ULN.
- •Inadequate renal function, defined as serum creatinine >2.0 mg/dl or >177 micromol/l
- •Proteinuria >1g in a 24-hour urine collection (to be performed only among patients who showed a ≥3+ at urine dipstick).
- •Patient related
- •Pregnant or lactating patients.
- •History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or sub-arachnoid haemorrhage within ≤6 months prior to the first study treatment).
- •Uncontrolled hypertension (sustained systolic >150 mm Hg and/or diastolic >100 mm Hg despite antihypertensive therapy) or clinically significant (i.e. active) cardiovascular disease, including:
- •myocardial infarction or unstable angina within ≤6 months prior to the first study treatment
- •New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)
- •serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)
- •peripheral vascular disease ≥grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision).
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the first study treatment.
- •Non-healing wound, ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require three weekly wound examinations.
- •Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
研究组 & 干预措施
First-line chemotherapy with bevacizumab
Other
- Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles
- Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
- Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
干预措施: Bevacizumab (Drug)
First-line chemotherapy with bevacizumab
Other
- Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles
- Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
- Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
干预措施: Paclitaxel (Drug)
First-line chemotherapy with bevacizumab
Other
- Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles
- Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
- Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
干预措施: Carboplatin (Drug)
结局指标
主要结局
expression of soluble and tissutal biomarkers
时间窗: measured at baseline, at completion of chemotherapy, at disease progression or bevacizumab completion up to 15 monthsfor each patient
次要结局
- overall survival(three years)
- number of patients taking oral antidiabetic therapy(at baseline)
- progression free survival(one year)
- number of patients taking antithrombotic therapy(at baseline)
- worst grade toxicity per patient(evaluated every 3 weeks up to 15 month)
研究者
研究点 (47)
Loading locations...
相似试验
进行中（未招募）
3 期
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian CancerRecurrent Ovarian CancerNCT01802749National Cancer Institute, Naples406
招募中
2 期
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabOvarian, Fallopian Tube and Primary Peritoneal CarcinomaNCT06141265Peking University Cancer Hospital & Institute116
已完成
不适用
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast CancerMetastaticBreast CancerNCT01745757UNICANCER510
已完成
2 期
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal CancerColorectal CancerNCT00483834University Health Network, Toronto50
已完成
3 期
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian CancerGenital Diseases, FemaleOvarian DiseasesOvarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsNCT01462890AGO Study Group927